Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)

Historical Holders from Q2 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AMPH on Nasdaq
Shares outstanding
46,377,939
Price per share
$26.78
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
32,746,950
Total reported value
$872,755,662
% of total 13F portfolios
0%
Share change
-135,006
Value change
+$25,427
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
239
Price from insider filings
$26.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Zhang Jack Y. 25% $301,456,363 12,524,153 Jack Y. Zhang 31 Dec 2024
BlackRock, Inc. 12% $142,136,789 5,333,463 BlackRock, Inc. 30 Sep 2025
As of 30 Sep 2025, Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) has 239 institutional shareholders filing 13F forms. They hold 32,746,950 shares. of 46,377,939 outstanding shares (71%) .

Top 25 institutional shareholders own 54% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 5,485,057 -3.2% 0% $146,176,770
VANGUARD GROUP INC 5.7% 2,631,040 -2.1% 0% $70,117,216
TD Asset Management Inc 4.2% 1,931,892 -5.1% 0.04% $51,484,922
DIMENSIONAL FUND ADVISORS LP 3.8% 1,755,665 +7.9% 0.01% $46,789,114
STATE STREET CORP 3.2% 1,500,742 -4.8% 0% $39,994,774
FULLER & THALER ASSET MANAGEMENT, INC. 2.9% 1,353,927 +7.1% 0.12% $36,082,167
Boston Trust Walden Corp 2.5% 1,173,107 -0.28% 0.23% $31,263,302
Epoch Investment Partners, Inc. 2.4% 1,133,986 -8.7% 0.17% $30,220,727
GEODE CAPITAL MANAGEMENT, LLC 2% 922,577 -5.2% 0% $24,590,067
MARSHALL WACE, LLP 1.9% 874,068 +3% 0.03% $23,293,911
MILLENNIUM MANAGEMENT LLC 1.5% 697,765 +13% 0.01% $18,595,437
RENAISSANCE TECHNOLOGIES LLC 1.3% 586,900 +1.8% 0.02% $15,640,885
MORGAN STANLEY 1.2% 574,679 -16% 0% $15,315,209
D. E. Shaw & Co., Inc. 1.1% 517,222 +76% 0.01% $13,783,966
SYSTEMATIC FINANCIAL MANAGEMENT LP 0.91% 423,112 +18% 0.27% $11,275,974
NORTHERN TRUST CORP 0.86% 399,470 -5.1% 0% $10,645,876
ALGERT GLOBAL LLC 0.85% 392,902 +216% 0.18% $10,471,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.85% 392,310 +383% 0.01% $10,455,062
Invesco Ltd. 0.84% 389,593 +0.68% 0% $10,382,654
ROYCE & ASSOCIATES LP 0.79% 366,322 +29% 0.1% $9,762,481
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.77% 356,409 +2.8% 0% $9,498,300
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 0.7% 326,183 -11% 0.03% $8,692,777
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.67% 312,337 +267% 0.18% $8,323,781
UBS Group AG 0.67% 312,274 +367% 0% $8,322,102
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.63% 292,443 -10% 0.03% $7,793,606

Institutional Holders of Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 250,313 $6,704,341 +$1,572,107 2,677.98% 7
2025 Q3 32,746,950 $872,755,662 +$25,427 2,665% 239
2025 Q2 32,731,709 $751,532,890 -$21,672,562 2,296% 243
2025 Q1 33,249,489 $963,158,808 -$63,190,016 2,899% 240
2024 Q4 35,163,514 $1,305,816,189 -$16,188,647 3,713% 261
2024 Q3 35,330,537 $1,713,563,419 +$41,888,246 4,853% 276
2024 Q2 34,395,410 $1,376,025,520 +$31,905,251 4,000% 268
2024 Q1 33,566,615 $1,473,434,135 -$321,352 4,391% 271
2023 Q4 33,295,380 $2,059,042,180 +$87,201,045 6,185% 273
2023 Q3 32,003,084 $1,472,015,140 +$20,443,300 4,599% 253
2023 Q2 31,353,069 $1,801,848,806 +$73,791,648 5,747% 241
2023 Q1 30,206,509 $1,132,914,126 +$45,004,448 3,750% 216
2022 Q4 29,163,019 $817,271,726 -$23,406,379 2,802% 208
2022 Q3 29,873,966 $840,021,516 -$35,843,317 2,810.01% 196
2022 Q2 30,557,166 $1,062,910,134 +$40,970,389 3,478.95% 217
2022 Q1 29,830,020 $1,070,980,758 +$25,890,372 3,589.99% 201
2021 Q4 29,169,816 $678,795,680 +$19,582,653 2,329.05% 165
2021 Q3 27,926,297 $530,762,683 +$12,225,786 1,900.98% 136
2021 Q2 27,261,956 $549,556,724 +$25,712,540 2,015.97% 142
2021 Q1 26,031,138 $476,843,577 +$545,086 1,831.97% 129
2020 Q4 25,994,308 $522,683,040 -$2,775,804 2,011% 126
2020 Q3 26,220,579 $491,828,114 -$4,779,592 1,875% 131
2020 Q2 26,338,746 $591,056,212 +$55,460,558 2,246% 132
2020 Q1 23,920,591 $355,117,215 -$14,172,545 1,484.05% 105
2019 Q4 24,555,993 $473,689,883 +$9,587,777 1,929.04% 116
2019 Q3 24,085,264 $477,743,008 +$39,111,793 1,983.03% 130
2019 Q2 22,325,317 $471,212,995 +$11,702,564 2,110.99% 129
2019 Q1 22,418,206 $457,984,013 +$3,993,993 2,043% 133
2018 Q4 22,224,435 $442,228,625 +$31,389,222 1,990.03% 129
2018 Q3 20,634,989 $396,966,940 +$11,955,958 1,923.99% 104
2018 Q2 20,104,298 $306,846,558 -$10,112,452 1,526.01% 110
2018 Q1 20,667,512 $387,520,854 +$4,863,050 1,875.04% 114
2017 Q4 20,638,746 $396,981,826 +$6,676,577 1,923.97% 104
2017 Q3 20,292,672 $362,569,441 -$2,721,250 1,786.99% 100
2017 Q2 20,446,108 $365,150,134 +$4,539,252 1,786.01% 106
2017 Q1 20,427,180 $296,235,043 +$42,154,775 1,450.04% 114
2016 Q4 22,346,694 $411,905,913 +$7,350,529 1,842.01% 135
2016 Q3 22,197,017 $421,063,192 +$114,569,375 1,896.95% 134
2016 Q2 16,184,121 $261,086,844 +$32,114,465 1,611.93% 104
2016 Q1 14,259,461 $171,232,000 -$8,847,105 1,200% 93
2015 Q4 14,731,020 $209,636,387 +$12,973,432 1,423.01% 93
2015 Q3 13,587,192 $158,819,188 -$3,114,129 1,168.99% 91
2015 Q2 13,322,195 $234,151,768 +$48,772,625 1,758.02% 85
2015 Q1 10,590,488 $158,146,254 +$40,390,095 1,496.01% 57
2014 Q4 7,933,683 $92,124,442 +$5,403,296 1,161.04% 54
2014 Q3 7,242,472 $84,362,000 +$80,866,904 1,164.48% 44
2014 Q2 300,000 $3,003,000 +$3,003,000 1,001% 2